2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Matthew Galsky, MD, discusses the design and findings of the phase 3 CheckMate 274 trial in urothelial cancer.
Matthew Galsky, MD, professor of medicine, hematology and medical oncology, professor of urology, director of Genitourinary Medical Oncology, codirector, the Center of Excellence for Bladder Cancer, and associate director, Translational Research at The Tisch Cancer Institute, Mount Sinai, discusses the design and findings of the phase 3 CheckMate 274 trial (NCT02632409) in urothelial cancer.
The CheckMate 274 trial is evaluating the utilization of adjuvant nivolumab (Opdivo) vs placebo in patients with high-risk, muscle-invasive urothelial cancer.
The primary end point of the trial is disease-free survival (DFS) in the all-comer and PD-L1–positive populations, Galsky says. It will be important to evaluate the subset of patients with tumors expressing PD-L1 is relevant because nivolumab is a PD-1 antibody, and testing for the target may enrich the patient population who will benefit, Galsky explains.
Initial results from the trial, which read out with a minimum of 5.9 months of follow-up, showed a significant improvement in DFS with adjuvant nivolumab compared with placebo in the intent-to-treat and PD-L1–positive populationsacross the patient population, Galsky continues. Based on this data, the FDA approved adjuvant nivolumab on August 20, 2021, Galsky concludes.